Oxaliplatin
| Code | Size | Price |
|---|
| TAR-T0164-50mg | 50mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T0164-100mg | 100mg | £125.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T0164-200mg | 200mg | £164.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
| TAR-T0164-500mg | 500mg | £182.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Oxaliplatin inhibits DNA synthesis by conforming DNA adducts.
CAS:
61825-94-3
Formula:
C8H14N2O4Pt
Molecular Weight:
397.294
Pathway:
Autophagy; Cell Cycle/Checkpoint; DNA Damage/DNA Repair
Purity:
0.9993
SMILES:
[Pt++].[O-]C(=O)C([O-])=O.N[C@@H]1CCCC[C@H]1N
Target:
DNA Alkylator/Crosslinker; DNA/RNA Synthesis; Autophagy
References
1. Raymond E et al, Ann Oncol, 1998, 9(10), 1053-1071.
10. Huang Y, Wang H, Hao Y, et al. Myeloid PTEN promotes chemotherapy-induced NLRP3-inflammasome activation and antitumour immunity[J]. Nature Cell Biology. 2020: 1-12.?22-6 , 716?727?
2. Mohammed MQ, et al. Anticancer Drugs, 2000, 11(10), 859-863.
3. Kirstein MN, et al. Anticancer Drugs, 2008, 19(1), 37-44.
4. Pendyala L, et al. Cancer Res, 1993, 53(24), 5970-5976.
5. Espinosa M, et al. Cancer Chemother Pharmacol, 2005, 55(3), 301-305.
6. Zhou Y, Yang L, Xiong L, et al. KIF11 is upregulated in colorectal cancer and silencing of it impairs tumor growth and sensitizes colorectal cancer cells to oxaliplatin via p53/GSK3? signaling[J]. Journal of Cancer. 2021, 12(12): 3741.
7. Dong L, Shen S, Chen W, et al. Discovery of Novel Inhibitors Targeting Human O-GlcNAcase: Docking-Based Virtual Screening, Biological Evaluation, Structural Modification, and Molecular Dynamics Simulation[J]. Journal of chemical information and modeling. 2019, 59(10): 4374-4382.
8. Yang P, Liu W, Fu R, et al. Cucurbitacin E Chemosensitizes Colorectal Cancer Cells via Mitigating TFAP4/Wnt/?-Catenin Signaling[J]. Journal of Agricultural and Food Chemistry. 2020
9. Wang X, Wu F, Wang H, et al. PDCD6 cooperates with C-Raf to facilitate colorectal cancer progression via Raf/MEK/ERK activation[J]. Journal of Experimental & Clinical Cancer Research. 2020, 39(1): 1-15.